Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

267
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
267
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

197
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
197
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

231
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
231
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

267
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
267
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

449
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
449

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Applying Public Health Principles to Better Manage the COVID-19 Pandemic: "Community Participation," "Equity," and "Cultural Sensitivity".

Asia-Pacific journal of public health·2021
Same author

Health system and quality of care factors contributing to maternal deaths in East Java, Indonesia.

PloS one·2021
Same author

Medicines information in medical journal advertising in Australia, Malaysia and the United States: A comparative cross-sectional study.

Southern med review·2012
Same journal

The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH.

Expert review of pharmacoeconomics & outcomes research·2026
Same journal

Comparative landscape of artificial intelligence-assisted systematic literature reviews.

Expert review of pharmacoeconomics & outcomes research·2026
Same journal

Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective.

Expert review of pharmacoeconomics & outcomes research·2026
Same journal

Real-world direct medical costs and resource utilization of immune checkpoint inhibitors in advanced NSCLC with COPD: a multicenter cost-consequence analysis from Iraq.

Expert review of pharmacoeconomics & outcomes research·2026
Same journal

TENS in chronic pain management: a 11-year nationwide analysis using the French National Health Data System.

Expert review of pharmacoeconomics & outcomes research·2026
Same journal

Economic burden of breast cancer in Cyprus from a societal perspective.

Expert review of pharmacoeconomics & outcomes research·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Price and utilisation differences for statins between four countries.

Loc Phuoc Thai1, Agnes Isabelle Vitry1, John Robert Moss2

  • 1a Quality Use of Medicines and Pharmacy Research Centre , Sansom Institute, University of South Australia , Adelaide , Australia.

Expert Review of Pharmacoeconomics & Outcomes Research
|August 12, 2017
PubMed
Summary
This summary is machine-generated.

New Zealand and England

Keywords:
Internationaldemand-side measuresdrug utilisation researchgenericspharmaceutical expenditureprice indicesstatins

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique
06:14

Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique

Published on: October 6, 2022

2.3K

Related Experiment Videos

Last Updated: Feb 24, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique
06:14

Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique

Published on: October 6, 2022

2.3K

Area of Science:

  • Pharmacoeconomics
  • Health policy analysis
  • Pharmaceutical market research

Background:

  • Different national policies influence medicine markets, affecting drug utilization and pricing.
  • Comparative analysis of pharmaceutical regulation is crucial for understanding market dynamics.

Purpose of the Study:

  • To compare statin prices and utilization across Australia, England, France, and New Zealand between 2011 and 2013.
  • To evaluate the impact of national regulatory policies on pharmaceutical markets.

Main Methods:

  • Utilisation data measured in Defined Daily Doses (DDD) per 1000 inhabitants per year.
  • Price and utilisation comparisons using pairwise Laspeyres and Paasche index methods.

Main Results:

  • New Zealand exhibited the lowest statin prices; Australia was most expensive in 2011-2012, with France being more expensive in 2013.
  • Significant discrepancies between Laspeyres and Paasche indices were observed when comparing England with Australia and France.
  • England and New Zealand demonstrated more effective policies in reducing expensive statin prices.

Conclusions:

  • England and New Zealand's policies effectively reduced the prices of expensive statins.
  • England showed the highest utilization of cheaper statins, influencing index result differences.
  • Australia's pricing policies have only partially succeeded in lowering statin costs compared to other nations.